ArticleMedComm2026
Machine Learning-Driven Noninvasive Prediction of Liver Fibrosis in Unclassified Liver Disease.
Article in MedComm, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic liver diseases (CLDs) frequently progress silently to advanced fibrosis or cirrhosis, yet existing predictive models have largely been developed for patients with clearly defined etiologies. Here, we asked whether a noninvasive machine-learning model based on routine clinical variables and liver stiffness measurement (LSM) could accurately identify significant liver fibrosis in patients with CLD of uncertain etiology, and whether such a model would add value beyond conventional fibrosis scores for clinical decision-making. We retrospectively analyzed 503 patients who underwent liver biopsy at Union Hospital, Tongji Medical College, Huazhong University of Science and Technology. Twelve machine-learning algorithms were trained to predict significant hepatic fibrosis, and model interpretability was assessed using SHapley Additive exPlanations. The best-performing model was then compared with four established noninvasive tools: FIB-4, GPR, Forns Index, and LSM alone. Among all candidate models, Categorical Boosting delivered the most favorable overall diagnostic performance, achieving the highest discriminative accuracy (AUC, 0.827; 95% CI, 0.754-0.900) and outperforming all conventional comparators across key classification metrics. We therefore establish an interpretable and clinically applicable panel integrating serological markers, age, LSM for noninvasive fibrosis assessment in patients with undefined or clinically ambiguous liver disease, with potential to reduce unnecessary biopsy and enable earlier intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.